Our first experience with intravitreal injection of brolucizumab

Abstract

Purpose. To evaluate the effectiveness of a new anti-VEGF drug in the treatment of patients with neovascular form of age-related macular degeneration. Material and methods. This study included 12 patients diagnosed with neovascular form of age-related macular degeneration. 7 people had previously received anti-VEGF therapy and 5 patients were primary. All patients received 3 consecutive loading doses of brolucizumab (Visque, NOVARTIS PHARMA STEIN, AG). Results. After the 1st injection of the drug brolucizumab, BCVA increased to 0.52 ± 0.28, after the 3rd injection to 0.57 ± 0.25 (p = 0.047). TCZV after the 1st injection decreased to 389 ± 110.8, after the 3rd 345 ± 114.23 (p= 0.057). Conclusions. According to our first observations, brolucizumab is an effective drug in the treatment of the exudative form of age-related macular degeneration, but further research is needed to study the comparative efficacy with other anti-VEGF drugs, analyze the qualitative characteristics and long-term results of the treatment. Keywords: age-related macular degeneration, anti-VEGF therapy, brolucizumab, optical coherence tomography.